Mosaic Therapeutics in-licenses clinical oncology programmes from Astex Pharma
Ella Day | April 25, 2025 | News story | Clinical Trial Services, Industry Associations, Mergers and Acquisitions, Research and Development | Astex pharmaceuticals, Mosaic Therapeutics, Oncology, clinical trial
Two clinical-stage oncology programmes from Astex Pharmaceuticals have been announced by Mosaic Therapeutics, allowing it to develop targeted oncology drug combinations. This elevates the research and platform company to a clinical-stage oncology business, bringing products closer to commercialisation and market access.
Mosaic now has exclusive rights to develop its combination products in these trials. The company develops therapeutics that combine oncology drugs which anticipate greater effectiveness than achieved with conventional monotherapy. This is since the approach seeks a broader biomarker-defined label across multiple tumour types.
The company will trial ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist, both developed by Astex. Through early trials, the two have been deemed able for combination use.
As part of the agreement, Astex has taken an equity stake in Mosaic, both upfront and dependent on clinical milestones. It will also receive potential future revenue shares.
Edward Hodgkin, chair of Mosaic Therapeutics, commented on the agreement: “The in-licensing of these two clinical-stage assets provides a step change in our development pipeline, allowing Mosaic to progress targeted drug combinations.”
Furthermore, CEO of Astex Harren Jhoti, stated: “We recognise the significance of Mosaic’s platform, which has identified these two assets as anchor components of a pipeline of potential combination products.”
He added: “We are excited to be working with the experienced team at Mosaic to expand the company’s pipeline in combination therapies with high unmet medical need.”
Ella Day
25/4/25
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
